New Companies & Technologies ReportBioMimetic Therapeutics develops drug‐device combinations using biologically active growth factor to stimulate tissue growth and repair. ... This

New Companies & Technologies Report March 2009

NCTRglobal survey of emerging and disruptive healthcare companies and technologies

New Companies and Technologies Report OneMedPlace Intelligence Services

Copyright © 2009. Not for redistribution. This bi-weekly report of new healthcare and life sciences technologies and companies is part of the OneMedPlace Intelligence Services, which includes access to the OMPTV Closed Circuit and Quarterly Investment Digests. For subscription information, please visit: www.onemedplace.com

Issue 2 March 2009 Aethon provides automated robotic workflow and asset management systems that can improve the efficiency of the healthcare sector. Telemedicine BioMimetic Therapeutics develops drug‐device combinations using biologically active growth factor to stimulate tissue growth and repair. Regenerative Medicine Caldera Medical develops and markets products designed to support female pelvic floor muscles, which can reduce or eliminate the occurrence of pelvic floor prolapse and female stress urinary incontinence. Urology Calypso Medical has developed a four‐dimensional localization system, dubbed the “GPS for the Body”, that gathers accurate and continuous information regarding tumor location in the prostate. Imaging eSight develops wearable display technology intended to address vision impairments not correctable by surgery or traditional eyeglasses, as well as to enhance visual experiences for sports fans and concertgoers. Ophthalmology

Endosense pioneered the use of contact force measurement in catheter ablation for the treatment of cardiac arrhythmias, including atrial fibrillation. Cardiology

Exactech provides implants, instrumentation and biologics for the restoration of bones and joints that have deteriorated from injury or chronic conditions. Orthopedics

Fibrogen researches and develops novel therapeutic molecules and recombinant proteins for an array of applications, ranging from fibrosis treatment to chronic heart failure. Wound Care

Hema Metrics facilitates the non‐invasive measurement of blood parameters in critical and intensive care applications. Patient Monitoring Hemobiotech is focused on developing and commercializing the first viable human blood substitute, based on its bovine hemoglobin‐based solution. Immunology Keraderm is preparing to commercialize its light‐based treatment for nail and skin infections. Infection Control

New Companies and Technologies Report OneMedPlace Intelligence Services

Copyright © 2009. Not for redistribution. This bi-weekly report of new healthcare and life sciences technologies and companies is part of the OneMedPlace Intelligence Services, which includes access to the OMPTV Closed Circuit and Quarterly Investment Digests. For subscription information, please visit: www.onemedplace.com

Issue 2 March 2009 Life Record is developing and marketing personal health record systems for use on mobile devices, including the iPhone and Blackberry Storm. Telemedicine LifeSync offers a wireless ECG data communication system that frees patients from traditional leads, while improving clinical outcomes. Patient Monitoring Live Tissue Connect provides a patented surgical tissue bonding and sealing platform that reconnects human soft tissue in a quick, airtight, leakproof and bloodless manner using high frequency bipolar energy. Surgery MicroDose is developing novel drug delivery platforms, including a fixed‐dose‐combination drug delivery system enabling the combination of two or more drugs into a single capsule. Drug Delivery Neuronetics uses transcranial magnetic stimulation to develop neuromodulation technology for the treatment of chronic psychiatric and neurological disorders, including depression that cannot be addressed with conventional drug therapies. Neurology Novalar offers the first FDA‐approved pharmaceutical agent indicated for the reversal of soft‐tissue anesthesia and the associated functional deficits resulting from local dental anesthetic. Dental Phreesia offers a free, swipe‐card enabled and wireless touch‐screen tablet that can serve as a substitute for check‐in clipboards and patient registration forms at doctors' offices, which can potentially enhance the efficiency and quality of medical care. Software Systems Ultrashape has developed the first clinically and scientifically proven non‐invasive fat reduction and body contouring device for both men and women. Aesthetics Viventia Biotech develops anti‐cancer drugs combining the potency of traditional cancer therapies with the precision of tumor‐targeting monoclonal antibodies. Diagnostics

Symbol PrivateExchange PrivateFounded 2001

Employees

OneMedPlace Investment Database Company Profile

__ | 1 of 1 | ___ Updated: Mar. 09

Aethon100 Business Center DrivePittsburgh , PA USA , 15205phone: 412-322-2975fax:www.aethon.com

Research Sector Medical Devices & TechSummary DescriptionAutomated Robotic Delivery and AssetManagement Systems for HealthcareApplicationsKeywordsrobotics, asset management, delivery,medications, efficiencyManagementAldo Zini, President & CEO; Robert Reilly, ChiefFinancial Officer; Spencer Allen, ChiefTechnology Officer; Peter Seiff, VP of CustomerSolutions; Peter Seiff, Vice President ofCustomer Solutions; Brian Curren, VP ofProfessional Support Services; David Wolfe,Director of Project Management

DescriptionAethon specializes in healthcare supply chain logistics and workflowsolutions providing a broad range of departmental and hospital-wideapplications that automate the movement of goods (such asmedications, supplies, meals, equipment, etc.), improve asset utilization,and ensure regulatory compliance. Technology/DifferentiationTUG's on-board computer contains a programmed map of the building,as well as sensors continuously tracking its location on the map. Usingthis information, it can ring a doorbell to notify its arrival to closed-offareas. The device has a matrix of 'light whiskers' to detect andcircumvent people and obstacles, consisting of sonar, infrared and lasertechnologies for outstanding sensing capabilities in all situations.Additionally, Aethon provides an elevator interface panel to work with allmajor elevator manufacturers; TUG communicates with the panel to callthe elevator and selects the floor using a wireless signal. It also sendswireless signals to automatic door openers on hallway doors. TUGavoids interference by operating at significantly higher radiofrequencies than other hospital systems, equipment or devices, and iscompatible with multiple communication options, including pagers andVOIP phones. Products/ServicesAethon delivers its solutions through a proprietary autonomous mobilerobot, the TUG, which has been shown to reduce cost, enhance clinicalproductivity, improve workflow and allow clinicians to devote more timeto their patients. The TUG is designed to transport a wide variety of cartsweighing up to 500 pounds (e.g., pharmacy, linen, dietary and mail) andto run errands, such as delivering charts, transporting blood samplesand picking up late meals. It also provides a cost-effective andnon-disruptive infrastructure for asset tracking, leveraginginterference-free RFID technology to locate missing equipmentthroughout the hospital and saving thousands of dollars in purchase andrental expenditures while reducing staff time normally wasted onsearching for equipment when needed. TUG's functions can beconfigured to accommodate the needs of specific users anddepartmental procedures. Market/CustomersMore than 100 hospitals have deployed Aethon's technology. TUGs havedemonstrated ROIs in the 20 to 50 percent range, while improving nurseand patient satisfaction. The market for healthcare robots is expected toreach $14 billion by 2014. StatusAethon announced in December 2008 that it had developed a patent-pending replenishment solution for Automated Dispensing Cabinets(ADCs) in hospitals. Designed to automate inventory replenishmentusing the existing TUG system, it is the first technology on the marketthat can remotely control cabinets in order to enable efficientrestocking. Aethon received additional funding for a phase II study aftercommencing its partnership with RE2 in November 2008.

OneMedPlace Investment Digest Company Profile http://www.onemedplace.com/database/compdisplay_print.lasso?Compa...

1 of 1 3/6/2009 4:18 PM

Symbol BMTI

Exchange NASDAQFounded 1999

Employees 85


__ | 1 of 1 | ___ Updated: Mar. 09

BioMimetic Therapeutics389-A Nichol Mill LaneFranklin , TN USA , 37067phone: 615-844-1280fax: 615-844-1281www.biomimetics.com

Research Sector Biotech Specialty PharmaSummary DescriptionDrug-Device Combination Products to treatMusculoskeletal InjuryKeywordsOrthopedics, spine, ortho joint, reconstruction,ortho joint, reconstruction, advamed, bonefracturesManagementSam Lynch, D.M.D., D.M.Sc., President, ChiefExecutive Officer; William Beasley, Director;Larry Bullock, Chief Financial Officer; EarlDouglas, General Counsel; Steve Hirsch,Executive Vice President; John McKay, VicePresident; James Monsor, Vice President; RussPagano, Ph.D., vice president of regulatory andclinical affairs; Leo Snel, Senior Vice President

Ownership Financials Mkt Cap : 175

* numbers in thousands

1 QTR | 1 YR | 5 YR

Revenue Outlook

DescriptionBioMimetic Therapeutics, Inc. develops bio-active drug-devicecombination products to speed the healing of musculoskeletal injuriesand diseases in periodontal, orthopedic, craniofacial, spine and sportsinjury indications. The company's products combine recombinantprotein therapeutics with tissue specific scaffolds to actively stimulatetissue healing and regeneration. Technology/DifferentiationBioMimetic's GEM and Augment products utilize the FDA-approvedrecombinant human platelet derived growth factor (rhPDGF-BB) incombination with scaffolding materials that have a history ofdemonstrated safety and efficacy. rhPDGF-BB attracts cells necessaryfor tissue healing through chemotaxis, while also stimulating an increasein the number of healing cells through mitogenesis; these processesexpand the number of cells available for the repair process. In addition,published in vivo and in vitro studies demonstrate that rhPDGF-BB mayenhance processes important in new blood vessel formation at thewound site, a process critical for wound healing. Consequently,rhPDGF-BB has been shown to enhance bone fracture repair and tostrengthen the skeleton throughout the body. Products/ServicesBioMimetic's GEM 21S is an FDA-approved product used to treat boneloss experienced in periodontal disease. The Augment Bone Graft(formerly GEM OS1 Bone Graft) is designed to stimulate boneregeneration; its targeted uses are in open fracture reduction and forfractures requiring surgery (foot and ankle fusion). Augment Bone Graft(formerly GEM OS2 Bone Graft) is an injectable product for boneaugmentation and for the treatment of non-surgical fracture injuries.Cartilage, ligament and tendon product candidates (Augment C andAugment LT) using proprietary technology are also being developed tostimulate cartilage, ligament, and tendon repair and regeneration. Market/CustomersAccording to Espicom, the global orthobiologics market was estimated tobe worth $4.2 billion in 2007 with an annual growth rate of 17%. Thoughstill in its early stage, orthobiologics is the fastest growing orthopedicsegment and presents vast opportunities for investment. StatusAs of December 31, 2008, 436 patients were enrolled in Biomimetic'sNorth American pivotal clinical study assessing the safety and efficacyof the Augment Bone Graft; the company closed enrollment for thisstudy in January 2009. Deloitte ranked Biomimetic Therapeuticsnumber 181 on its 2008 Technology Fast 500, which ranks the 500fastest growing technology, media, telecommunications and lifesciences companies in North America. Since BioMimetic's dentalbusiness is now owned by Luitpold Pharmaceuticals, the company isprimarily focused on its orthopedic products and product candidates.


1 of 1 3/6/2009 5:50 PM


Employees


__ | 1 of 1 | ___ Updated: Mar. 09

Caldera Medical28632 Roadside Drive, Suite260Agoura Hills , CA USA ,91301-6099phone: 818.879.6555fax: 818.879.6556www.calderamedical.com

Research Sector Medical Devices & TechSummary DescriptionSling Systems Counteracting Pelvic FloorProlapseKeywordswomen's health, womens, womenshealth, urologyManagementBryon L. Merade, CEO; Dov Tamler, VP ofBusiness Development and Operations; SandraMuhlfeld, Director of Marketing; Albert Beran,Director of Sales and Marketing, InternationalMarkets

DescriptionCaldera Medical focuses exclusively on developing and marketingproducts in gynecology, urology, and urogynecology. The company'sofferings are designed to support the pelvic floor muscles and to reduceor eliminate the occurrence of prolapse. Prolapse is a condition arisingwhen weak muscles no longer provide adequate support for the pelvicfloor area and/or genital tissues, thereby enabling the upper portion of apelvic organ to descend within (or protrude outside of) the body. Technology/DifferentiationDesara is designed to meet surgeons' needs for open knit constructionmerging increased flexibility with stability. The mesh design of the slingsystem is constructed from large pore microfilament polypropylene, andits tapered tips enable optimal placement and help reduce tissue trauma.The sleeve design of Desara allows for precise tension adjustments,smooth guidance through tissue and mesh protection duringimplantation; a gap in the sleeve helps surgeons easily locate the centerof the sling during placement. Centrasorb is composed of apolydioxanone suture weave that is absorbed in one hundred days. Atthat point, fibroblastic ingrowth of the mesh and central section providesupport to patients with long-term incontinence while minimizing theopportunity for erosion. The Hydrix XM, derived from non-cross linkedbovine pericardium, decellularizes and stabilizes the tissueimmunologically; bovine cells are removed from the pericardium, whilethe extracellular matrix serves as a scaffold for human pelvic floor celldevelopment. It is processed using the patented Veritas Collagen Matrixdeveloped by Synovis Surgical Innovations. Products/ServicesCaldera's trademarked product pipeline includes: the Desara slingsystem for the treatment of female stress urinary incontinence andvaginal vault prolapse (the upper portion of the vagina drops into oroutside the vaginal canal); the T-Sling with Centrasorb, acentimeter-wide absorbable central section placed directly under theurethra; and the Hydrix XM, a treatment for pelvic organ prolapse. Market/CustomersProlapses occur only in women and become more common withincreasing age, although one major study has found that half of thewomen seeking care are between 30 and 60 years of age. The UnitedStates currently spends over $10 billion per year on pelvicreconstructive surgery and $26 billion to manage urinary incontinence-acommon symptom of prolapse-in patients over sixty-five years of age. StatusDesara received CE Marking in September 2007. In January 2008,Caldera Medical signed a patent license agreement with Coloplast A/Sgranting Caldera sole custody of patent rights (among privately heldcompanies) related to the transobturator method used to treat femalestress urinary incontinence.


1 of 1 3/6/2009 5:51 PM


Employees


__ | 1 of 1 | ___ Updated: Mar. 09

Calypso MedicalTechnologies4th & Blanchard Building,2101 Fourth Avenue, Suite500Seattle , WA USA , 98121phone: 206-254-0600fax: 206-254-0606www.calypsomedical.com

Research Sector Medical Devices & TechSummary Description4D Imaging to Track Prostate Motion and TumorLocationKeywordsdelivery, cancer, target localization, Beacontransponder, radiation, advamedManagementEric Meier, President and Chief ExecutiveOfficer; J. Nelson Wright, Executive VicePresident and Chief Technology Officer; StevenDimmer, Vice President, Research andDevelopment; Edward Vertatschitsch, Ph.D.,Vice President, Engineering; Mark Querry, VicePresident, Finance and Administration; LynnPurdy, Vice President, Marketing; James Shock,Vice President, Sales; John Stevens, VicePresident, Manufacturing; Marcia Page, SeniorDirector, Quality Assurance & Regulatory Affairs;Lisa Skrumeda-Levine, Ph.D., Senior Director,Clinical Research

DescriptionCalypso Medical Technologies, Inc. is a privately-held medical devicecompany focused on improving the accuracy of radiation therapy. Thecompany addresses two major issues in modern radiation oncology:errors in treatment set-up and tumor motion during treatment. Technology/DifferentiationThe technological platform of the Calypso 4D Localization System isbased on the detection of electromagnetic markers, or Beacontransponders. The Beacon transponders, each smaller than a grain ofrice, are permanently implanted in the prostate before external beamtherapy. Once inside the patient, they transmit safe radiofrequencywaves to the Calypso system that represent objective locationinformation. The 4D Electromagnetic Array contains the ACelectromagnetic source that excites the Beacon transponders andpossesses receivers that detect the transponders' positions; it is placedover the patient during external beam therapy. The 4D Array is acomponent of the 4D Console, which also houses the processormodule, power source, and control panel. The Console transfers data tothe 4D Tracking Station, which continuously monitors tumor positioninformation in real time and generates daily reports. The finalcomponent of the Calypso 4D Localization System is the OpticalSystem, which consists of three infrared cameras determining theposition of the 4D Electromagnetic Array. Due to these intricatecollaborations among its various technologies, the Calypso 4DLocalization System exhibited sub-millimeter electromagnetic localizationaccuracy without additional non-ionizing radiation (according tophantom measurements under typical conditions of actual use). Products/ServicesThe company's signature product, the Calypso 4D Localization System(also known as GPS for the Body), can provide objective, accurate andcontinuous information regarding tumor location. The system alsodisplays and records real-time prostate motion during treatment deliveryvia its intuitive graphical user interface. Clinicians may then use the datagenerated by the system to guide radiation therapy setup and to makecorrections during treatment delivery if the target falls outside ofacceptable boundaries, thereby functioning as a GPS for the Body. Inaddition, the Calypso 4D Localization System's non-ionizingelectromagnetic guidance has been found to improve work flowefficiency and treatment room utilization. The Calypso technology isdesigned to monitor and treat various cancers undergoing widespreadmetastasis (i.e. breast and lung). As of July 2006, the FDA grantedCalypso 510 (k) clearance to utilize its technologies solely in prostateapplications. Market/CustomersAbout 1.4 million cases of cancer are diagnosed annually in the UnitedStates. Over 1.1 million individuals receive some form of radiationtherapy for cancer (according to the National Cancer Institute), whichprovides some insight on how medical radiation equipment evolved intoan approximately $2 billion per year industry. StatusCalypso announced in May 2008 that its GPS for the Body has beenFDA-cleared for use in prostatectomy patients in addition to patientswith intact prostates. In January 2009, Calypso announced that DukeUniversity Medical Center was the first in the country to install the latestversion of its 4D Localization System, featuring its recently-releasedAdaptive Workflow Efficiency option, to optimize radiation treatment forits cancer patients. The upgradeable system option includes AdaptiveCouch Repositioning, which provides connectivity between the CalypsoSystem and Varian Medical Systems' 4D integrated treatment console(4DITC) to allow an immediate on-line response to organ motion.


1 of 2 3/6/2009 5:54 PM


Employees


__ | 1 of 1 | ___ Updated: Mar. 09

EndosenseChemin du Grand Puits 42,1217 MeyrinGeneva , Switzerland ,phone: 41 22 306 19 60fax: + 41 22 306 19 79www.endosense.com

Research Sector Medical Devices & TechSummary DescriptionCatheter Ablation to treat Cardiac ArrhythmiasKeywordsatrial fibrillation, arrhythmias, ablation, forcesensor, catheterManagementEric Le Royer, President & Chief ExecutiveOfficer; Giovanni Leo, Co-founder & ChiefTechnology Officer; Michael Grau, ChiefFinancial Officer; Eric Giroud, Director, QualityAssurance & Regulatory Affairs

DescriptionEndosense is a privately-held Swiss company focused on enabling thebroad adoption of catheter ablation for the treatment of cardiacarrhythmias, including atrial fibrillation (AF). Technology/DifferentiationEndosense has pioneered the use of contact force measurement incatheter ablation. Developed using fiber optic sensor technology,Touch+ provides highly accurate and sensitive measurements at theablation catheter tip. The intuitive interface enables a physician to bettercontrol force amplitude and direction. Products/ServicesThe TactiCath is the first force-sensing ablation catheter to providephysicians with a real-time, objective measure of contact force betweenthe catheter and the beating heart wall, allowing electrophysiologists todeliver the appropriate force to the appropriate lesions. Market/CustomersAF is currently the most common cardiac rhythm disorder, affectingmore than six million people worldwide. Endosense is focused onproviding this sizeable patient population with a minimally invasivetreatment option that is both safe and effective. (Most AF patients aretreated with ineffective and side effect-inducing pharmaceutical drugs,with the primary alternative being invasive ablation surgery.) StatusAfter undergoing extensive preclinical testing in the United States andEurope, the first human trial of TactiCath commenced in Europe inOctober 2008. TactiCath was awarded the ISO 13485:2003 certificationfor its quality management system in August 2008, a significant steptoward CE approval (expected in 2009) and FDA clearance. The deviceis currently limited to investigational use by the U.S. FDA.


1 of 1 3/6/2009 5:58 PM


Employees 7


__ | 1 of 1 | ___ Updated: Mar. 09

eSight Corporation350 Terry Fox Drive,Ottawa , ON Canada , K2K2W5phone: 613-271-9535fax: 613-271-0066www.esightcorp.com

Research Sector Medical Devices & TechSummary DescriptionWearable Display Technology to Correct forVision ImpairmentsKeywordsVision technology, vision impairments, wearablevision displayManagementConrad Lewis, Chairman; Dan Mathers President& CEO; Pat Beirne, Chief Technology Officer;Mr. Rob Hilkes, Vice President, Marketing andBusiness Development; Roger Colbeck,Engineering Advisor; Dan McCarthy, ChiefFinancial Officer

DescriptioneSight Corporation utilizes its proprietary image processing algorithmsto develop wearable display technology. The company's products areintended for those with vision impairments not correctable by surgery ortraditional eyeglasses, and for individuals seeking to enhance theirvisual experiences (e.g., sports fans and concertgoers). Technology/DifferentiationeSight technology leverages digital image and video capture, softwareimage processing and advanced display techniques to optimize theremaining functional regions within a person's field of vision. Thedevices are the first of their kind to be calibrated to the specific visualneeds of a patient, which are determined by preferred day-to-dayactivities. Products/ServiceseSight's wearable display products are equipped with integrated cameraand pupil tracking components, a portable computer platform andproprietary image processing software. The technology may beincorporated into glasses resembling conventional sunglasses orheadsets incorporating video display screens, among the manyavailable forms. Market/CustomerseSight is targeting patients with age-related macular degeneration(ARMD), diabetic retinopathy, glaucoma, retinitis pigmentosa and anassortment of other retinal diseases. It will cater to a market that spends$8 billion on vision correction and $20 billion on sporting events. Anestimated three to four percent of the U.S. population has serious visualimpairments that cannot be treated via surgery; the percentage is likelyto grow as the baby boomer generation ages and the increase inobesity leads to an increase in diabetes (a common cause of visualimpairments). StatusAs of September 2007, eSight has developed a prototype that integratesthe early technology and is showing it to investors. Early clinical testingwith severely visually impaired subjects at Hotel Dieu hospital inKingston, Canada, has provided very encouraging results, showingimprovements in reading speed and comprehension, image contrastperformance, and facial recognition.


1 of 1 3/6/2009 5:59 PM

Symbol EXACExchange NASDAQFounded 1985

Employees 265


__ | 1 of 1 | ___ Updated: Mar. 09

Exactech2320 North West 66th CourtGainesville , FL USA , 32653phone: 352-377-1140fax: 352-378-2617www.exac.com

Research Sector Medical Devices & TechSummary DescriptionOrthopedic Implant Devices and BiologicalMaterials for SurgeryKeywordsreconstruction, orthopedicsManagementWilliam Petty, M.D., Chairman, Chief ExecutiveOfficer; David W. Petty, President, Director; JoelC. Phillips, CPA, Chief Financial Officer; Gary J.Miller, Ph.D., Executive Vice President,Research and Development; Gary J. Miller,Ph.D., Executive Vice President, Research andDevelopment; Bruce Thompson, Senior VicePresident, General Manager, Biologics Division



1 QTR | 1 YR | 5 YR

Revenue Outlook

DescriptionExactech develops and markets orthopedic implant devices, relatedsurgical instruments and biologic materials and services to hospitals andphysicians in Europe, Asia, Latin America, Australia, and the UnitedStates. Exactech's orthopedic products are used in the restoration ofbones and joints that have deteriorated from injury or chronicconditions. Technology/DifferentiationThe Novation and AcuMatch lines use two emerging technologies:Connexion GXL enhanced polyethylene acetabular liners, which providea low wear rate while maintaining an appropriate level of fracturetoughness; and Low Plasticity Burnishing (LPB), a patented processimparting residual compressive stresses to the surfaces of metal parts toenhance fatigue strength and reduce crack initiation. Features of theOptetrak line include: the patented Ligament Balancing System, whichuses the patient's soft tissue to determine the ideal external rotation ofthe femoral component; Low Profile Instrumentation (LPI), which givessurgeons the flexibility and independence to use their proven techniqueswhile customizing the procedure for each patient; and the ability toadjust the joint line of primary knee implants. Optecure's roomtemperature composition facilitates rapid mixing with buffer solution,blood, or autogenous bone grafts. Regenaform and Regenafil containdemineralized freeze-dried bone allograft, which provides for theformation and development of bony tissue. The Interspace CementSpacers are pre-formed, partial load-bearing devices consisting ofgentamicin-impregnated Cemex PMMA bone cement. Cemex features aunique self-contained delivery system integrating both the bone cementpowder and liquid into an enclosed mixing system. Products/ServicesExactech's product lines address the following areas: hips, knees,shoulders, biologics for orthopedic reconstructive surgery, bonecement, cement spacers, and dental biologics. The Optetrak is acomprehensive total knee implant designed to decrease contact stress,enhance patellar tracking, decrease polyethylene wear, improve jointstability and bone preservation with streamlined instrumentation forquick and efficient surgery; this line accounts for about 54% of thecompany's revenue. Acumatch femoral stems and endoprosthesesfacilitate hemiarthroplasty (replacing the ball of the hip joint), while theNovation line provides stable reconstruction and bearing surfaces forthe hip. Optecure is an engineered bone graft for reconstruction of thespine, pelvis and extremities. Exactech has also developed the Equinoxeline for shoulder surgery, three lines of dental allograft paste, bonecement products, and a platelet concentrating system. Market/CustomersNearly one million knee replacement procedures are performedworldwide each year. On a global scale, industry analysts predict 8%annual growth in the $4.6 billion worldwide knee replacement market and6% annual growth in the $5.2 billion hip replacement market. Theworldwide orthopedic market is nearly $29 billion, and growing at 10.7%annually. StatusExactech announced in February 2009 that it had extended itsrelationship with the Hospital for Special Surgery, an orthopedicshospital based in New York, to further advance implant designs for totalknee replacement surgery. The company is also planning the limitedrelease of an upgraded version of its Optetrak knee implant in thesecond half of 2009.


1 of 1 3/6/2009 6:00 PM


Employees


__ | 1 of 1 | ___ Updated: Mar. 09

Fibrogen409 Illinois StreetSan Francisco , CA USA ,94080phone: 415-978-1200fax: 415-978-1902www.fibrogen.com

Research Sector Biotech Specialty PharmaSummary DescriptionTherapeutic Molecules and Recombinant Proteinsfor Several Applications, including FibrosisKeywordsFibrosis, Pathological Scarring, CTGF, TGF-beta,Kidney Fibrosis, Arteriosclerosis, Hypoxia-Inducible Factor, EPOManagementThomas B. Neff, Chairman, Founder, ChiefExecutive Officer; Pat Cotroneo, Vice President,Finance, and Chief Financial Officer; MelissaGrigorieff Koomey, Vice President, Marketing,Corporate Communications and InvestorRelations; William Hodder, Vice President,Business Development; Wilbert LeeSenior VicePresident of Administration; Al Lin, MD, Ph.D.,Vice President, Preclinical Development; DavidY. Liu, Ph.D., Vice President, Research; ClaireJ. Lockey,Vice President, Regulatory Affairs;James W. Polarek, Vice President, Collagen andGelatin Development; Leanne C. Price, VicePresident, Intellectual Property;Ted Tucker, VicePresident, Human Resources

DescriptionFibroGen was founded for the purpose of discovering, developing andcommercializing novel therapeutics that stop fibrosis (pathologicalscarring). The company's therapeutics and product candidates addressunmet needs in several fields, including diabetes, anemia, and tumorprogression and metastasis. Technology/DifferentiationFibroGen's proprietary screening assays are used to identify andevaluate novel small molecule inhibitors as potential anti-fibrotictherapeutics. The company then uses these small molecules-novel HIFprolyl hydroxylase inhibitors (HIF-PHI)- to direct certain aspects of thebody's hypoxia-inducible factor (HIF) system for clinical benefit. HIF isan important regulatory protein that orchestrates the body's emergencyresponse system to hypoxia (inadequate levels of cellular oxygen). Uponactivation, HIF coordinates expression of genes mediating cellular andphysiological responses to protect against tissue damage and cell death,as well as restore oxygen balance. The company produces itsrecombinant human collagens and gelatins using in-house fermentationcapacity. Products/ServicesFibroGen's lead clinical candidate is FG-3019, a fully human monoclonalantibody that targets connective tissue growth factor (CTGF). Whensecreted, CTGF mediates communication between various cell typesand the extracellular matrix (surrounding environment) and therebycontributes to the progression of fibrosis and proteinuria (among otherconditions). Other product candidates include FG-2216 and FG-4592,erthyropoietic drugs in Phase II clinical trials for the treatment of anemiain chronic kidney disease patients (The former drug is also beingevaluated for use in chronic inflammatory disease). FG-5030 isrecombinant human collagen (type III) formulated as an injectabledermal filler for use in cosmetic applications. Fibrogen is alsoconducting research to develop a cost-effective, scalable plant-basedsystem for the co-production of recombinant proteins (i.e., collagensand gelatins). Market/CustomersAnti-CTGF therapy offers potential clinical benefits in diverse areas,including chronic heart failure, pancreatic cancer and liver and lungfibrosis. HIF-PHI therapy can be used to treat inflammation and anemia.The company's recombinant proteins are designed for medical,pharmaceutical and agricultural applications (e.g., ethanol as a gasolineadditive and corn oil for lubricants in motor vehicles). StatusRecent research results (February 2009) from the Stanford UniversitySchool of Medicine indicates that CTGF inhibition could yieldtherapeutic benefits in the treatment of pancreatic cancer. Thecompany resumed recruitment for its Phase II study of theinvestigational Oral HIF-PH Inhibitor, FG-4592/ASP1517, for thetreatment of anemia associated with chronic kidney disease in January2009. Fibrogen is also enrolling patients for Phase I trials of FG-3019investigating applications in diabetic kidney disease, focal segmentalglomerulosclerosis and pancreatic cancer.


1 of 1 3/6/2009 7:02 PM

Symbol PrivateExchangeFounded 2001

Employees


__ | 1 of 1 | ___ Updated: Mar. 09

Hema Metrics695 North 900 WestKaysville , UT USA , 84037phone: (800) 546-5463fax: (801) 451-9007www.hemametrics.com

Research Sector Medical Devices & TechSummary DescriptionNon-Invasive Blood Parameter MeasurementKeywordsblood, parameter, oxygen saturation, patientmonitoring,ManagementWendell Gene Pickett, Chairman of the Board;Patrick Moriarty, President and Chief ExecutiveOfficer; Lee Barrett, VP Manufacturing; MichaelBlack, VP Sales & Marketing; Matt Haynie,Western Sales Manager; Mark Pinson, EasternSales Manager; Diana Hlebovy, R.N., B.S.N.,C.H.N., C.N.N., Director of Clinical Affairs

DescriptionHema Metrics is a medical device company using existing patents inoptical technology to provide solutions for the non-invasive measurementof blood parameters, including hematocrit and hemoglobin levels,percent oxygen saturation and percent blood volume change. Technology/DifferentiationA disposable cuvette connected to the arterial side of the dialyzer andin-line with the blood tubing set allows the Crit-Line III to non-invasivelymonitor whole blood parameters. Patented optical technology shinesnear-infrared light through the blood, specifically measuring thescattering and absorption characteristics of the red blood cell. Theproprietary ratio metric formula provides real-time hematocrit andoxygen saturation. Fluid management using hematocrit-based bloodvolume monitoring has been shown to optimize dry weights, reducehospitalizations and minimize hypovolemic symptoms. The addition ofTQA (Transcutaneous) Access Blood Flow capability to the Crit-Line IIIenables immediate assessment of the blood flow rate of hemodialysisaccess (before, during or after dialysis), rendering lengthy and difficultblood line reversal unnecessary. Comprised of light emitting diodes andflexible silicon rubber detectors, the TQA Sensor Pad essentially "sees"the blood in the vessel when properly positioned over the access. A 20ml bolus of normal saline dilutes the blood momentarily, and reflects thepercentage change of hematocrit detected through the skin andmeasured by the TQA system. Products/ServicesCrit-Line III-TQA is a fluid management and access monitoring toolincorporating photo-optical technology into the measurement of absolutehematocrit, percent blood volume change, continuous oxygen saturationand access recirculation. The TQA monitor downloads access flowmeasurements, synchronizing this information with existing data withinthe patient file. Hema Metrics has developed record-keeping softwareplatforms in addition to its devices. The TQA Access Manager is aWindows-based access management program that maintains basicpatient information, access revision histories and patient-specificaccess failure thresholds, while the Crit-Line Reporter Softwaredownloads raw data from the Crit-Line monitor to a Windows-basedcomputer and prepares several time plots of blood parameters. Basicpatient information is kept along with these information plots, allowingeasy access to each dialysis round monitored by the Crit-Line III. Market/CustomersThe Crit-Line III enables non-invasive optical measurement of absoluteblood parameters in areas such as hemodialysis, congestive heartfailure and volume control of intensive care and critical care patients.Hema Metrics is investigating further applications and new markets toimprove outcomes for volume-overloaded patients. StatusThe Crit-Line and its associated products are FDA 510(k) cleared, CEMark approved and CLIA exempt. Hema Metrics announced in June2008 that fluid management is a covered condition under new CMSinterpretive guidelines. The company developed compliance solutionsfor these guidelines in October 2008.


1 of 1 3/6/2009 6:01 PM

Symbol HMBTExchange .OBFounded 2001

Employees 5


__ | 1 of 1 | ___ Updated: Mar. 09

Hemobiotech, Inc.5001 Spring Valley Road,Suite 1040- WestDallas , TX USA , 75244phone: 972-455-8950fax: 972-455-8951www.hemobiotech.com/

Research Sector Biotech Specialty PharmaSummary DescriptionBovine Hemoglobin-based Human BloodSubstituteKeywordsblood substitute, oxidative stress, inflammatoryresponses, transfusions of red blood cells, j2008ManagementArthur P. Bollon, Ph.D., Chairman of the Boardof Directors, President and Chief ExecutiveOfficer; Mark J. Rosenblum, C.P.A., ChiefFinancial Officer; Mario Feola, M.D., ChiefMedical Officer; Jan Simoni, Ph.D., D.V.M.,Acting Vice President, Research andDevelopment and Advisor



1 QTR | 1 YR | 5 YR

Revenue Outlook

DescriptionHemoBioTech, Inc. is a biopharmaceutical company focused ondeveloping and commercializing the first viable human blood substitute,which consists of bovine hemoglobin. Technology/DifferentiationThe development of HemoTech is based on HemoBioTech's proprietaryplatform technology involving the chemical modification of hemoglobin.The modified hemoglobin is designed to diminish the intrinsic toxiceffects of natural hemoglobin, as well as eliminate the abnormalreactions resulting from the loss of blood during hemorrhage and fromsubsequent decreases in blood pressure and other vital signs.HemoTech is created by reacting pure bovine hemoglobin with threecompounds: o-adenosine 5- triphosphate (o-ATP), o-adenosine andreduced glutathione (GSH). o-adenosine counteracts the hemoglobinproperties that cause the narrowing of blood vessels and reduceshemoglobin's ability to cause inflammation, while GSH modifies thesurface charge of HemoTech so that its oxygen affinity is lowered. Products/ServicesThe company's lead product, HemoTech, is designed to perform similarfunctions and demonstrate similar properties to red blood cells, includingoxygen-carrying and anti-inflammatory activities. HemoTech alsoreplenishes the native blood supply via erythropoiesis, the production ofred blood cells within the body. Unlike blood, HemoTech is compatiblewith all blood types, can be administered within minutes and has a shelflife of over six months (compared with the average blood shelf life of 42days). Due to these properties, HemoTech may help reduce or eliminatethe dangerous consequences of traumatic acute blood loss. Market/CustomersHemoTech addresses an increasing yet unmet demand for safe andinexpensive blood domestically and internationally, and can represent amarket valued between $7-$14 billion in the United States alone. Thecompany's technologies also have applications in the pharmaceuticaland cosmetic industries. StatusHemoBioTech is preparing to file an Investigational New Drug (IND)application for HemoTech with the FDA in order to start clinical trials inthe United States. The company received an exclusive worldwide licensefrom the Texas Tech University System in May 2008 for a noveltechnology acting to prevent the spread of prions and viruses in animal-derived products for human use.


1 of 1 3/6/2009 6:02 PM


Employees


__ | 1 of 1 | ___ Updated: Mar. 09

Keraderm144 Research DriveHampton , VA USA , 23666phone: 757-344-8607fax:www.keraderm.com

Research Sector Medical Devices & TechSummary DescriptionPhototherapy Treatment for Skin and NailInfectionsKeywordsSkin Infection, Nail Infection, Phototherapy, NailTreatmentManagementBill Cumbie, President/CEO

DescriptionKeraderm is dedicated to harnessing the healing power of light to treat awide variety of skin disorders and nail infections. Technology/DifferentiationKeraderm's light-based technology has the potential to effectively treatinfections without the serious side effects arising from othermedications. The company has obtained patents on its key technologiesto treat infections and has additional patent applications pending onrefinements of its technology. Products/ServicesKeraderm's proprietary phototherapy treatment has shown potentialefficacy in pilot clinical trials, and is the only patented germicidal lightnail treatment available to date. It is currently used to treat nail fungus(onychomycosis) and represents a potential treatment for psoriasis andMRSA-related skin infections. Market/CustomersAccording to the Virginia Biotechnology Association, onychomycosisaffects approximately 36 million Americans and the current treatmentmarket is approximately $1.5 billion. Keraderm's technology is in line tobecome the first FDA-approved treatment for this condition, as no safeand effective alternatives are yet available on the market. StatusKeraderm announced in September 2008 that it had completedenrollment for its placebo-controlled, double-blind, multi-site trialinvestigating the use of phototherapy in onychomycosis patients. Thecompany Keraderm anticipates FDA clearance for its treatment in earlyto mid-2009 and is seeking its first round of venture capital fromaccredited investors or venture capital funds.


1 of 1 3/6/2009 5:46 PM


Employees


__ | 1 of 1 | ___ Updated: Mar. 09

Life Record403 West Broadway, Suite133Bloomfield , NM USA , 87413phone: 877-577-3727fax:emr.liferecord.com

Research Sector Medical Devices & TechSummary DescriptionPersonal Health Records System Compatible withMobile DevicesKeywordsEMR, PHR, health records, medical records,imaging, telemedicine, software systemsManagementRobert J. Singer, M.D, Founder

DescriptionLife Record Inc. specializes in the development and marketing ofmedical record technology, releasing the first web-based EMR inSeptember 1998 for use in medical practices and entering the personalhealth record market with Life Record EMR in June 2007. Life RecordEMR enables patients to view and take control of their health recordsoutside of the physician's office, wherever is most convenient for them;the latest version of the company's software is compatible with variousplatforms (i.e., PC, Mac and Linux) and 'smartphones' (including theBlackberry Storm, iPhone and Google Android). Technology/DifferentiationIn 1998, Life Record developed the world's first web-enabled medicalrecord software based on the Intersystems Cache database. Thecompany's current EMRs are currently fully-functional web-enabledEMR applications built on new open and non-proprietary technologies,including PHP and MySQL. Life Record EMR offers tight integration withmultimedia technologies, which allows incorporation of simple andadvanced imaging techniques. As an example, When combined with theFree Open Source next generation DICOM viewer, Osirix, DICOMimages and animations are easily added to the patient chart and viewedat the touch of a finger on an iPhone. LifePax technology createselectronic versions of existing papers currently used by physicians andadds tablet PC entries into the patient record. Products/ServicesFeatures of the Life Record EMR include EMRAnywhere (a toolenabling e-prescribing and quick decision-making in urgent situations)and InLobby Enrollment (which transfers patient information directly tothe electronic medical record after check-in). ChartAnywhere providesphysicians with remote access to a patient's complete medical record,including but not limited to: laboratory results, active prescriptions,diagnostic images and physician notes. Using a 20-digit ChartAnywherecode, referring physicians can also view and add information directly tothe patient's medical record; primary physicians are immediatelynotified of any revisions to the record. Patients can use the same codeto access their record via web browser; while they cannot changerecords, they may store and send questions and comments to theirphysicians via ChartAnywhere's secure communications platform. LifeRecord entries cannot be changed by third parties, such as insurancecompanies. Market/CustomersTo date, more than 3000 physicians have used the My Life Record EMRsoftware for their practices to organize patient information. KaloramaInformation predicted in 2007 that the $1.2 billion annual EMR marketwill grow 14.1% each year over the next eight years; greater gains areexpected with the recent $20 billion stimulus provision for EMRdevelopment and implementation. Commercial editions of the LifeRecord software are available for individual or family use. StatusLife Record released Version 5.0 of its EMR in December 2008 andannounced its 'immediate availability' for the Google Android and theBlackBerry Storm.


1 of 1 3/6/2009 3:14 PM


Employees


__ | 1 of 1 | ___ Updated: Mar. 09

LifeSync CorporationOne East Broward Blvd. -Suite 1701Fort Lauderdale , FL UnitedStates , 33301phone: (866) 324-3888fax: (954) 745-7654www.lifesynccorp.com

Research Sector Medical Devices & TechSummary DescriptionWireless ECG Data Communication SystemKeywordsMedical device company, ECG System,Electrocardiogram, Diagnostic technologies,LifeSyncManagementShelley A. Hartman, Chairman of the Board,President and Chief Executive Officer; Lou AnnBeggs, Senior Vice President of Sales andMarketing; Nancy McLane, Senior VicePresident Operations; Mark J. Phelps, SeniorVice President of Research and Development;Jeffrey L. Raney, Secretary and GeneralCounsel

DescriptionLifeSync Corporation is a medical device company dedicated to thecontinued development, marketing and sale of wireless vital signacquisition products. The LifeSync Wireless ECG System is the firstwireless electrocardiogram data communication system appropriate foruse in hospital and outpatient settings where cardiac ECG andrespiration monitoring are required. Technology/DifferentiationBased on Bluetooth technology, the LifeSync System interfaces withexisting patient monitoring equipment and allows health facilities tomonitor patients wirelessly. The patient transceiver is worn by thepatient, while the monitor transceiver is placed near the ECG monitor;both function as two-way radios collecting and transmitting ECG andrespiration data. Standard ECG electrodes are attached to theLeadWear Disposable product, which replaces traditional leads andmay be purchased in configurations that allow for 3/5 or 12 lead patientmonitoring. Its radiolucency ensures unobstructed chest x-ray imagesand clear views under fluoroscopy. Products/ServicesThe LifeSync System is the first wireless electrocardiogram (ECG) datacommunications system appropriate for use in high acuity settings. Inaddition to being wireless, the LifeSync System can significantlyincrease accuracy of patient alarms and decrease risk of hospitalacquired infections. It is comprised of the company's DisposableLeadwear product and electronic equipment, including a patienttransceiver (PT) and a monitor transceiver (MT). The LifeSync Systemfrees patients from the traditional lead wires that connect them tobedside monitors. Market/CustomersThe global market for wireless medical technologies is expected to reach$10 billion by 2011. LifeSync's products are sold to hospitals and stresslabs across the United States. StatusLifeSync's products and systems are FDA approved, as well asapproved by the Federal Communications Commission (FCC) tooperate over public radio frequencies required for signal transmission.The company was awarded a multi-year contract with MedAssetsSupply Chain System, effective from February 1, 2009.


1 of 1 3/6/2009 6:03 PM


Employees


__ | 1 of 1 | ___ Updated: Mar. 09

Live Tissue ConnectTechnologies7200 Hollister AvenueSanta Barbara , CA USA ,93117phone: 805 961 4800fax: 805 961 4466www.livetissueconnect.com

Research Sector Medical Devices & TechSummary DescriptionBloodless Soft-Tissue Sealing System usingBipolar EnergyKeywordssurgery, tissue welding, medical device,bloodless, seal, fusion, wound careManagementFrank D'Amelio, President; Andrew Woodruff,Vice President of Research, Development, andEngineering; Bruce Thompson, PE ConsultingVice President of Financial Operations; DavidColvin, Director of Worldwide Sales andMarketing and General Manager of GeneralSurgery Gynecology Division

DescriptionLive Tissue Connect (LTC) Technologies' patented surgical tissuebonding/welding platform bonds and reconnects human soft tissue in aquick, airtight, leakproof and bloodless manner using high frequencybipolar energy. Technology/DifferentiationThe BioFuse sealing system is capable of sealing vessels as large asseven millimeters in diameter and withstanding a vessel burst pressureas high as seven times the normal systolic blood pressure. Thealgorithm of the BioFuse VAD.400 generator, powered by smart-chiptechnology, measures and processes multiple critical tissue variables toensure that the appropriate amount of energy is delivered to the targetedarea. In a process lasting mere seconds, the BioFuse sealing systemshrinks and denatures collagen and other cellular proteins within thetissue, which later enables permanent protein bonding with minimaltissue sticking and charring. The BioFuse automatic tissue analyzingsystem detects when the seal is completed and terminates energydelivery. The new seal is also created without the deposition of foreignmaterials potentially interfering with future diagnosis. Due to thediminished or eliminated leakage, scarring and tissue incompatibilityassociated with conventional wound closure tools (i.e., sutures, sealants,staples, and glues), LTC dubs its process 'foolproof automatic scarlesssurgery.' Products/ServicesLTC has established six divisions, each focusing on procedure-specificproduct designs: General Surgery & Gynecology Medical Group,Orthopedic Tissue Sciences, Colorectal Connection ManagementPulmonary Sealing Sciences, Urologic Tissue Welding, and AestheticTissue Welding. The BioFuse Tissue Sealing System (consisting of theVAD.400 bipolar generator, PCS. 900 open straight forceps, andPCC.900 open curved forceps) is a proprietary third generation radiofrequency (RF) bipolar tissue management system using a combinationof precisely calculated energy with physical pressure to seal and bondarteries, veins, ducts, and many other human soft tissues and organs. Market/CustomersIn its aim to be a global organization with worldwide distribution, LTC iscurrently marketing the BioFuse generator and forceps in the UnitedStates and to over thirty countries throughout Europe. The physician-focused company has conducted several clinical trials and oversawsurgical procedures on over 10,000 patients in Eastern Europe. StatusLTC was established as a subsidiary of Consortium ServiceManagement Group, Inc. in 2007. It received FDA 510(k) clearance tomarket its BioFuse generator and forceps in July 2008 and was laterawarded the CE Mark Certificate for its forceps in September 2008. Thecompany next plans to implement its USA sales representativerecruitment plan and ramp up production for distribution. LTC currentlyholds a total of 16 patents and 15 patent applications pending worldwiderelating to its BioFuse Sealing System.


1 of 1 3/6/2009 6:04 PM


Employees


__ | 1 of 1 | ___ Updated: Mar. 09

MicroDose Technologies4262 US Route 1Monmouth Junction , NJ USA, 08852phone: 732-355-2100fax: 732-355-2101www.microdose-tech.com

Research Sector Medical Devices & TechSummary DescriptionPulmonary, Oral, and Fixed-Dose CombinationDrug Delivery PlatformsKeywordsChronic Disease, Asthma, COPD, DIabetes,drug deliveryManagementAnand V. Gumaste, Chairman; F. Scott Fleming,Co-founder, Sr. Vice President, Head ofMarketing; Dave Byron, Vice President ofResearch and Development; Michael Martin, VicePresident, Licensing and CorporateDevelopment; John Krall, Senior Director,Finance; Rajesh B. Shukla, Senior Director; RonBritt, Director of Quality Assurance

DescriptionMicroDose Technologies is a privately-held drug delivery and specialtypharmaceuticals company pioneering the use of proprietary platformsfor pulmonary, oral and transdermal medication delivery for improvedefficacy and compliance. Technology/DifferentiationMicroDose has three core technology platforms: the MicroDoseElectronic Dry Powder Inhaler, the MicroDose Fixed-Dose-CombinationOral Dosage System, and the MicroDose Needlefree System.MicroDose DPI is a handheld, low-cost, breath-activated device thatutilizes piezo electronics to efficiently deliver a broad range ofcompounds, including compounds include small or large moleculetherapeutics for both local and systemic applications. The company'stechnology for solid oral dosage formats and enables the combination oftwo or more drugs into a single pill or capsule, but separated by aphysical barrier. This physical barrier, between two fixed doses, allowsfor more rapid development timelines and lower regulatory requirements,at a fraction of the normal cost. This proprietary approach may enablepatent extensions on blockbuster drugs whose patents are soon toexpire. MicroDose's needle-free delivery approaches encompassbattery-operated, electromechanical approaches controlling thenon-invasive injection of microliter quantities of a drug in rapid pulsesuntil the entire volume is delivered. Unlike systems using iontophoresisor electroporation, Microdose's needle-free delivery systems can deliverboth small and large molecules. Products/ServicesMicroDose's lead product is an electronically controlled Dry PowderInhaler (DPI) that achieves respiratory dose delivery independent ofinhalation flow rate. The company has also identified and is developingseveral combination products for its own use in the high growth areas ofhypertension, hyperlipidemia and Type II diabetes based on itsproprietary fixed-dose combination technology. (Advantages ofMicroDose's technology include shorter time-to-market, lowerdevelopment cost and easier manufacturing.) MicroDose's needle-freedelivery systems are safe and simple to use, inexpensive, quiet, and usedrugs prepackaged specifically for a unit dose pack to eliminatecleaning and assure correct dosing. Market/CustomersMicroDose's technology platforms represent opportunities in varioushigh-value markets, including asthma, COPD, diabetes, hypertensionand hyperlipidemia. StatusMicroDose's current intellectual property portfolio consists of thefollowing: 13 U.S. issued patents, 12 U.S. patent applications pending,10 internationally-issued patents, 44 international patents pending on aregional or specific country basis and 3 trademarks registered andpending in the U.S. and internationally. The company announced inAugust 2008 that it would collaborate with Merck in the execution of aphase I trial of its dry powder inhaler technology.


1 of 1 3/6/2009 5:04 PM


Employees 50


__ | 1 of 1 | ___ Updated: Mar. 09

NeuroneticsOne Great Valley Parkway,Suite 2Malvern , PA United States ,19355phone: (610) 640-4202fax: 610-640-4206www.neuronetics.com

Research Sector Medical Devices & TechSummary DescriptionNeuromodulation for Depression TreatmentKeywordsneurology, depression, psychiatryManagementBruce Shook, President & CEO; Mark Bausinger,CFO; Mark Demitrack, MD, Chief MedicalOfficer; Mark Riehl, VP Product Development &Operations; Peter Anastasiou, VP Marketing;Judy Ways, Ph.D., VP Regulatory Affairs &Quality Assurance; Stanford Miller, VP HealthPolicy & Access; Jim Breidenstein, VP Sales

DescriptionNeuronetics is a privately-held company developing non-invasivetreatments for chronic psychiatric and neurological disorders, includingdepression, based upon neuromodulation technology. Technology/DifferentiationUsing highly focused, MRI-strength magnetic field pulses, the NeuroStarsystem repetitively stimulates nerve cells located in an area of the brainlinked to depression to help normalize neurotransmitter function. ThePDMS includes: wireless connectivity with multiple NeuroStar systems,patient summary reports, diagnosis and current medicationdocumentation, and referring physician communications and tracking.Neuronetics' SenStar has four key functions: contact sensing to ensuretreatment coil is positioned correctly, magnetic field confirmation toensure patient receives desired treatment, surface field cancellation toreduce stimulation of the scalp and serving a hygiene barrier frompatient to patient. Products/ServicesThe company's NeuroStar TMS Therapy System treats majordepression in patients who have not responded to, or are intolerant of,drug therapy. NeuroStar TMS Therapy is a forty minute outpatientprocedure administered five times a week for four-six weeks. It does notrequire anesthesia or sedation, and can be performed in a psychiatrist'soffice. The Precise Data Management System (PDMS) custom softwareprogram is designed to streamline TMS treatment data. Additionally, theSenStar Treatment Link is a single-use patient interface device attachedto each treatment coil. Market/CustomersDepression affects at least 14 million American adults each year.Researchers estimate that by the year 2020, depression will be thesecond leading cause of disability worldwide. Each year, over 30,000people in the U.S. commit suicide, 60% of which had previouslysuffered from depression. Depression has no racial, ethnic, orsocioeconomic boundaries, though women are more often diagnosedwith the condition. About two-thirds of individuals who have experiencedan episode of depression will have at least one additional episode intheir lives. The market for antidepressant drugs is worth $12.5 billion,yet nearly 30% of patients with depression do not benefit from-or areintolerant of-antidepressant therapy. StatusNeuronetics announced on October 8, 2008 that its NeuroStar system isthe first and only non-systemic and non-invasive TMS therapy system toreceive FDA clearance for the treatment of depression, specifically inpatients who have not previously benefited from antidepressantregimens.


1 of 1 3/6/2009 6:05 PM


Employees


__ | 1 of 1 | ___ Updated: Mar. 09

Novalar Pharmaceuticals12555 High Bluff Drive, Suite300San Diego , CA USA , 92130phone: 858-436-1100fax: 858-436-1101www.novalar.com

Research Sector Biotech Specialty PharmaSummary DescriptionTargeted Oral Pharmaceuticals ReducingNumbness and Pain Following Dental ProceduresKeywordsOraVerse, NV-201, root canal, clindamycin,endodontist, dental, anesthesia, biotech, oralpharmaceutical, numbness, pain, swellingManagementDonna Janson, President and Chief ExecutiveOfficer; Robert S. Stefanovich, Chief FinancialOfficer; Laura A. Navalta, Senior Vice President,Clinical & Regulatory Affairsc; BruceRutherford,Vice President, Clinical Development;Diana P. Friedman, Vice President, Marketing;Jeffrey Lord, Vice President, Sales; DougBakan, Vice President, Product Development;

DescriptionNovalar is a specialty biopharmaceutical company addressing thecommon sources of patient discomfort following dental procedures,including the numbness associated with anesthesia and pain followingroot canals. The company states that it is uniquely positioned to developtargeted oral pharmaceutical products and translate the full value ofthese novel solutions to clinical practice. Technology/DifferentiationOraVerse is a clear, colorless, sterile, non pyrogenic, isotonic andpreservative-free solution. Phentolamine mesylate, the active ingredientin OraVerse, produces a relatively short alpha-adrenergic block that canvasodilate the targeted vascular smooth muscle. NV-201 provideslow-dose and targeted delivery of clindamycin into the root canal via anEVA fiber (that is removed prior to filling). Clindamycin is highlyeffective against gram negative organisms that commonly infect the rootcanal and are associated with symptoms like pain and swelling. Products/ServicesThe company's OraVerse injection is a FDA-approved local anestheticreversal agent accelerating the return of normal sensation and functionfollowing restorative and periodontal maintenance procedures. OraVerseis indicated for the reversal of soft-tissue anesthesia (i.e., anesthesia ofthe lip and tongue, and the associated functional deficits resulting froman intraoral submucosal injection of a local anesthetic containing avasoconstrictor). Novalar has also licensed the patent rights to NV-201,a novel endodontic therapy utilizing a polymer fiber to locally deliverclindamycin (a commonly used antibiotic) directly into a root canal forthe purpose of reducing the bacteria most often associated with inter-appointment pain. Market/CustomersApproximately 275 million cartridges of local dental anesthetic areadministered annually in the United States. Since there are currently noknown competitors to OraVerse, Novalar anticipates significantopportunities in the U.S and international markets, as well as interestfrom dentists and consumers alike. NV-201 could also present asignificant market opportunity; an estimated 17 million root canalprocedures are performed annually in the United States. StatusNovalar received FDA approval for OraVerse in May 2008. Thecompany published the results of its Phase 3 clinical studies in August2008, which vouched for the safety and efficacy of OraVerse inreducing the duration of soft tissue anesthesia in patients receivingstandard local anesthetic injections and in pediatric patients. Novalarlicensed the patent rights to NV-201 from the Forsyth Institute in June2007.


1 of 1 3/6/2009 6:06 PM


Employees 11


__ | 1 of 1 | ___ Updated: Mar. 09

Phreesia110 East 23rd Street, Suite400New York , NY USA , 10010phone: 888-654-7473fax: 646-607-1776www.phreesia.com

Research Sector Healthcare ServicesSummary DescriptionFree Wireless Touch-Screen Substitute forPatient Check-in ClipboardsKeywordsHP Conference, HealthIT, Healthcare IT,SoftwareSystems, wireless, touch-screen, touchscreen, patient intake, workflow, HIPAA,PhreesiaPad, consultation, Parkinson's, stroke,HP ConferenceManagementChaim Indig, CEO

DescriptionPhreesia aims to simplify the collection of medical records. Thecompany's products automate patient check-in and deliver fullyinteractive content directly to patients, and are designed to interfacewith physicians' existing and future technology. Technology/DifferentiationThe PhreesiaPad can reduce the amount of paperwork for patients andfront-desk staff, since patients verify current information rather thanfilling out the same forms each visit. Phreesia's screening questions andcomputer-based format can encourage patients to confide sensitive andmore accurate medical information, features which better preparephysicians in advance of their patients' visits and enhance in-officeconsultation. To address concerns over privacy, each PhreesiaPadcomes with a built-in tracking device as well as multiple anti-theftwarning signs to prevent theft. Furthermore, it does not operate outsideof a physician's office. Products/ServicesThe company's signature product, the PhreesiaPad, is a swipe-cardenabled wireless touch-screen tablet serving as a substitute for check-inclipboards at doctors' offices. In addition to automating data entry forfront office staff and securing patient signatures on all required HIPAAprivacy forms, doctors receive fully legible information that can be easilyaccessed from outside the office. Since Phreesia is a sponsorship-supported business, PhreesiaPads are free for qualified physicianpractices. Market/CustomersPhreesiaPads can be found in thousands of doctors' offices across theU.S. The company's technology is marketed to physicians' officesseeking to reduce staff workload while maintaining or enhancingworkflow. StatusPhreesia announced in February 2009 that it had closed an $11.6million investment round led by BlueCross Blue Shield Venture Partners,L.P. bringing total investment to date to $25 million. In the first half of2008, the company announced that it had integrated a new screeningtool into its electronic patient intake process for applications inParkinson's Disease and stroke. Phreesia was awarded the DEMOgodAward; DEMO previously launched TiVo, Palm Pilot, E*Trade,Salesforce.com and Skype.


1 of 1 3/6/2009 6:08 PM


Employees


__ | 1 of 1 | ___ Updated: Mar. 09

UltraShapeNew Industrial Park, POB 80Yoqneam , Israel , 20692phone: +972.4.9099200fax: +972.4.9592323www.ultrashape.com

Research Sector Medical Devices & TechSummary DescriptionNon-Invasive Fat Reduction and Body ContouringKeywordsaesthetics, plastic surgery, skin care, fatreduction, body contouring, ultrasound,liposuction, non-surgical alternativeManagementAssaf Eyal, President and Chief ExecutiveOfficer; Zvi Ben David, CPA, Chief FinancialOfficer; Avi Shalgi, Vice President of Research &Development; Robert E. Gerberich, President ofUltraShape NA, Inc. and Global Sales; RoniZomber, Vice President of Operations; EzraKatzen, General Counsel; Kris Foss, VicePresident Regulatory and Clinical; Itay Dromi,Vice President Human Resources

DescriptionUltraShape endeavors to redefine aesthetic medicine and enhance thelives of patients worldwide by developing, manufacturing and marketingnon-invasive technologies for body contouring. In particular, thecompany's proprietary non-invasive body contouring technology usesfocused ultrasound to target and selectively disrupt fat cells withoutaffecting surrounding structures. Technology/DifferentiationThe UltraShape Contour I uses a patented ultrasonic transducer todeliver controlled focused ultrasound at a precise depth within thesubcutaneous fat cell layer. The disrupted fat cell content is thentransported through the vascular and lymphatic systems to the liver,where it is processed in a similar manner to fat originating fromconsumed food. The UltraShape procedure is guided by proprietaryreal-time tracking and guidance technology designed to deliver smooth,uniform body contouring results. The software provides a predeterminedtreatment algorithm designed to minimize risk of contour irregularities, acommon side effect of liposuction. The system overcomes the obstaclesassociated with patient motion by recording and synchronizing thebody's position in real-time and in 3-D, thereby enabling the patient tomove freely without impacting the treatment. During the procedure, thetracking system ensures that each zone is treated only once andprohibits treatment outside the premarked zone, ensuring homogenouscoverage of the treatment area and a smoothness of the skin surface.Additionally, an integrated acoustic contact sensor provides real-timefeedback to ensure proper transducer-to-skin contact and efficientenergy delivery to the treatment area. Products/ServicesThe UltraShape Contour I system is the first scientifically and clinicallyproven non-invasive fat reduction and body contouring device, intendedfor use in average to overweight men and women seeking to removelocalized fat deposits without surgery. The device is designed toproduce mechanical, non-thermal and acoustic effects that target andselectively disrupt fat cells in the abdomen, thighs and back (i.e., sitesof 'love handles') without harming adjacent critical structures (i.e., skin,blood vessels, nerves, connective tissue). Each treatment lasts between60 and 90 minutes (depending on the size of the treatment area), andcan be performed in a physician's office without anesthesia. Patientsmay resume their daily routines immediately following the procedure, asa recuperation period is not necessary. Market/CustomersLiposuction is the most popular aesthetic surgical procedure in the U.S.,with just under 500,000 procedures carried out every year by certifiedplastic surgeons and 250,000 to 500,000 more procedures carried outby other surgeons. The market for body shaping treatments is expectedto increase by 21.6 percent annually in response to the growingdemand for liposuction; approximately 21.5 million procedures will beperformed in 2012 if growth remains constant. The UltraShapeprocedure is available in 57 countries, and over 100,000 patienttreatments have been performed worldwide with high patient satisfaction. StatusUltraShape reported that improvements to its software and transducercontributed to a 35 percent reduction in treatment time and shorterintervals between treatments (approximately 40-60 minutes) at the 2008European Academy of Dermatology and Venereology (EADV) annualmeeting in Paris. In addition, clinical studies conducted in France,Canada and Israel demonstrated the safety and efficacy of threesuccessive UltraShape treatments at two-week intervals. UltraShape'stechnology has received attention in the academic and mainstreampress, which includes an ABC News report originally aired in January2009. The Contour I received CE Mark approval in 2005, received aHealth Canada medical license in 2007 and is undergoing pivotal studiesin the United States (where the company is awaiting FDA approval).


1 of 2 3/6/2009 6:09 PM

Symbol PrivateExchangeFounded 1983

Employees


__ | 1 of 1 | ___ Updated: Mar. 09

Viventia Biotech5060 Spectrum Way Suite405Mississauga , OntarioCanada , L4W 5N5phone: 905-361-8686fax:www.viventia.com

Research Sector Biotech Specialty PharmaSummary DescriptionTumor-Targeting Monoclonal Antibodies andTarget Discovery TechnologyKeywordsbladder cancer, head and neck cancer, tumor,target, antibody, anti-cancer drugManagementNick Glover, Ph.D, CEO; Michael Byrne, CGA,CFO

DescriptionViventia Biotech Inc. is a private biopharmaceutical companydeveloping anti-cancer drugs that combine the potency of traditionalcancer therapies with the precision of tumor-targeting monoclonalantibodies. Technology/DifferentiationThe components of Viventia's proprietary technology seek to addressfundamental considerations in developing antibody-based therapeutics,such as choice of target, method of generation, mechanism of action;and production. The UnLock platform isolates and identifies novelmembrane-associated tumor markers; to date, it has identified 14 newpotential cell-surface targets for cancer drugs. Fusogenics generatesfully human monoclonal antibody libraries by leveraging the naturalimmune response of cancer patients. After testing with functional assay,resulting antibodies are expressed in a proprietary soluble functionallibrary and available for rapid, high content screening. Viventia'sImmunoMine platform is a high-throughput antibody screening processthat-through increasingly rigorous tests-rapidly sorts therapeuticallypromising tumor-specific antibodies from antibodies reacting withnormal cells. The company has also developed "Armed Antibodies",which utilize and combine small engineered antibody fragments for solidtumor penetration, recombinantly fused protein payloads for stableconjugation and decreased toxicity, and tumor-activated cytotoxicproteins designed to activate intracellularly and remain inert outside thecell for optimal safety and efficacy. Products/ServicesViventia's trademarked monoclonal antibody portfolio includes:Proxinium, which is currently in global Phase III trials for the treatmentof head and neck cancer; Vicinium, in phase II trials for the treatment ofbladder cancer; and VB6-845, a proprietary humanized antibodyfragment targeting metastatic cancers and currently in Phase I/II trialsfor the treatment of solid tumors. Market/CustomersAt least 400,000 Americans currently live with bladder cancer, withapproximately 60,000 new cases and 15,000 deaths attributed to thedisease annually. One particularly aggressive form, carcinoma in situ(CIS), does not respond reliably to the most common forms of localtherapy, BCG or chemotherapy. For many patients, CIS bladder cancerpersists following initial treatment and may ultimately require complete orpartial removal of the bladder. Bladder cancer is the fifth most commoncancer in North America, while head and neck cancer is close behind.Approximately 55,000 new cases of head and neck cancer arediagnosed annually in the U.S. alone, leading to 14,000 deaths eachyear. StatusProxinium currently has Orphan Drug status in the U.S. and Europe, aswell as a Fast Track product designation from the U.S. FDA. Viventiaplanned to file a Biologic License Application (BLA) for Proxinium in late2008. Additionally, it initiated patient treatment for the phase I trial ofVB6-845 in June 2007 and soon plans to conduct phase II trials. Thecompany announced positive results of its Vicinium Phase I/II trial,reporting that the drug partially or completely controlled the rate ofprogression of bladder cancer in 93% of its high risk study population.The company is actively investigating the relationship of certain targetsidentified via its UnLock platform, including CD44E and Glut-8, tocancer stem cells.


1 of 1 3/6/2009 6:10 PM

Envoy Medical BioControl MedicalCVRxEndovalveSynthemedCardiousEndosenseMedicureMitralignPlaCorPossis MedicalSymphony Medical, IncAcistCardioinsightCogentus PharmaceuticalsMiCardia CorporationMicrobia (now Ironwood Pharma)Neomed technologiesNeovasc, inc.PortolaReva MedicalValveExchangeAGA Medical CorporationAtritech, IncBacchus Vascular, IncCardiacAssist IncCardioFocus, IncCardiva Medical, IncDirect Flow MedicalElectrical Geodesics, IncMiTiHeart CorporationAcorn CardiovascularAlveolus Inc.Aptus Endosystems, IncArbor Surgical Technologies, Inc.CHF Solutions, Inc.Deca-Medics, Inc.Design Medical, IncNeochordEcardio diagnosticsCardiomag imagingAllvivo Vascular, IncGenesis Medical InterventionalPico-tesla Magnetic TherapiesNorthstarOmneuronRhinocyteNeuronetics, inc.AxoGenZogenixCSF TherapeuticsIntelect MedicalEMKinetics, IncAfferent CorporationCoAxia, InConcentric Medical, IncBiowaveNfocus Neuromedical Inc.Angel Medical Systems Prodrive SystemsNational Laser TechnologyNovalar PharmaceuticalsLerner MedicalAerolaseMinerva Healthcare Inc.Xthetix inc. CVAC SystemsGlucolight Corp.Inovise Medical, IncInterventional Imaging, IncMatritech, IncThe Radiology GroupCalypso MedicalCepheidNeoprobeRedpath Integrated PathologyScantek Medical, IncSenoRxSleep Solutions, IncsuperDimension20/20 gene systemsAllegro DiagnosticsApeliotus Vision scienceBD LabsBeckton DickinsonBiomarker StrategiesIkonisysMicrophage, inc.Nanomix Orla Protein TechnologiesQuidelVeralightLife MedicalNatural SelectionResponse GeneticsAdvanced liquid logics Dermtech InternationalLakewood PathMicronics, incNesos Health

Perceptronix MedicalProvista Life SciencesQDX PathologySpherosense TechT2 BiosystemsThe Elitech GroupMicromedicalStone Medical CorpTomo TherapyAperio Technologies, IncAcryMedChemica technologies, incCritical Care Innovations, inc.Mystic PharmaNovaDel Redpoint Freedom2IncGreat Basin scientifi cNexMedSagent PharmaceuticalsSoteiraISM Therapeutics

MicroDose Technologies, IncAffi nergy, inc. Revolutions MedicalMedLogixBioconnectsystemssyncro medical innovationsExcorp MedicalGentris Clinical Genetics, IncFossamedicaSeno Medical instrumentsAION diagnostics ltdBraccoMedical Digital DevelopersSAES GettersAdvanced Imaging Technologies, IncMicroMRI Inc.HoloradInfraRed Imaging Systems, IncInfrared Sciences CorpInfraScan IncLightLabDesigns For VisionHematechHoffman and Krippner, inc.Epitomics, Inc.ImmunoGenetix TherapeuticsTargantaAmsino International, Inc.KeradermAethlon MedicalUAMS BioventuresIncumed IncorporatedEcho Therapeutics Organic Extracts CorporationAmbit BiosciencesNanospectra BiosciencesPhoto Dynamic TherapyFibroGen, IncLight Sciences Oncology, Inc.CytonomeNeoVista, IncAxial BiotechIsto TechRS MedicalAmedicaAxioMed SpineBacterin International, IncBellacureBiomimetic Therapeutics IncExactech, IncInterventional Spine, IncKFx Medical CorporationSmall Bone InnovationsTibionVicthom Human BionicsDisc DynamicsUS Spine Inc.Apatech LTDCannufl ow, Incorporated

OrthomemsRestorative Physiology CrescentSherlock-NMDThe Orthotic GroupeSight Corp.Scientifi c IntakeCanregLogikos, Inc. Archimedes med techAmerican WellHealthlink EuropeTissue LinkNichibei Bio, IncGeneral AtlanticAccellaArlington medical resourcesFravimedAVDElcamOrsenseSymbios medical products

Therapeutic Monitoring systemsGet Well Network, inc.Lifesync CorporationMuveNewCare MedicalHeart One Global ResearchWaterfront MediaHemametricsInnerPulse, IncKeimarLife RecordPatholaseSole SolutionsDymedix CorpAeris Therapeutics, IncALung Technologies, IncCeption TherapeuticsViroNovativeActuality Medical, IncBoneGrafi x, Inc.MesynthesNanoVibronixNovamatrix/FMCXylos corpACell, Inc.AldagenBioring SAMastLab (MAST Biosurgery AG)HealionicsAethon IncHealthCare IT, IncClearcountDeltex MedicalMagforce NanotechnologiesmNemoscience GmbHPeak SurgicalCelonova BiosciencesCohera medicalAvedroKing SystemsSangartVision SciencesIdeal Implant IncorporatedNovare Surgical Systems, Inc.Force 3 MedicaleMedical CVKhorionyxKeren MedicalNovasys MedicalUrovalve IncAeterna ZentarisAureon LaboratoriesAuxilium PharmaceuticalsBioXell SpACaldera MedicalColoplastDiagnocureEigenEncore, Inc

Alaven Pharmaceutical LLCAllwin Medical DevicesAloka UltrasoundAndromeda Medical ServicesArizant Healthcare, Inc.ASSI-Accurate Surgical & Scientifi c InstrumentsAST Advanced Shockwave TechnologyAstra TechAugusta Medical Systems, LLCBelair Instrument CompanyBest Medical International, Inc.BiolitecBiosound EsaoteB-K Medical SystemsDiadexus, incRenal AdvantageAcentec inc.Acupath Laboratories, Inc.Calmoseptine, Inc.CBLPath, Inc.Contravac, Inc.Convergent Laser TechnologiesCytogen CorporationDalken LLCDirectory Assistants, Inc.Doc-tor.comDornier MedTechE-cathEDAP TMSElmed Lithotripsy SystemsEMS Electro Medical Systems S.AEndoControl MedicalEngineered Medical DevicesErbe USA, Inc.Ferring PharmaceuticalsFiberTech USAFMD, LLCFocus Surgery, IncForTec MedicalGlenwood, LLCGreenwald Surgical Company, IncGTx, Inc.Gyrus ACMI CorporationInnoGyn, IncItamal Medical LtdKarl Storz EndoscopyKeeler InstrumentsKensey Nash CorporationKlein SurgicalKyoto Kagaku Co., LtdLaborie MedicalLaser Peripherals, LLCLexion MedicalLife-Tech, Inc.Lisa Laser, USALumenisMarcap CorporationMedison America, Inc.Mediwatch PLCMETI-Medical Education TechnologiesMicroline PentaxMimic TechnologiesMolded Products, IncOmni Medical SystemsONC SolutionsOpticon Medical Inc.Q-Med Scandinavia, Inc.Richard Wolf Medical InstrumentsRochester Medical CorporationSightlineSontec InstrumentsSpectrum PharmaceuticalsSurgitel/General Scientifi cSurgRx Inc.Swan Valley MedicalTAP Pharmaceutical Products, Inc.T-Doc Company, LLCThe Prometheus GroupTherapak CorporationTri-anim Surgical SolutionsTrimedyne, Inc.United EndoscopyUnited Medical SystemsUrorad Healthcare, LPUS UrologicVascular TechnologyVasectomy.comWatson Pharma, Inc.3-Dmed Surgical Training AidsGalil Medical Qualigen, Inc.PD LabsImpres Medical, IncAthena FeminineClinical Cell Culture/Avita medNerites corp.Nitric BioTheragenicsInsense Ltd

Are you going to research all

these companies?

This is just a small sample of fi rms researched by OneMedPlace. Look out for these companies, and many more, in upcoming issues of the New Companies and Technologies Report (NCTR), a bi-weekly roundup of emerging companies offering the latest innovations in health and medicine.

global survey of emerging and disruptive healthcare com-panies and technologies

NCTR

Documents

New Companies & Technologies ReportBioMimetic Therapeutics develops drug‐device combinations using biologically active growth factor to stimulate tissue growth and repair. ... This